Article directory

July 2026 FDA advisory meeting

FDA Peptide Vote Results: BPC 157, Semax, TB 500 and More

A two day FDA advisory meeting produced favorable recommendations for six peptide related substances and an unfavorable result for one. Here is the accurate result, without confusing compounding eligibility with FDA drug approval.

Updated July 29, 2026Educational regulatory coverage8 minute read
Key point
This was not FDA drug approval.

The committee made nonbinding recommendations about potential Section 503A compounding eligibility. FDA still must decide what formal action, if any, to take.

The complete result

Seven substances reviewed. Six recommended.

Across July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee considered whether seven peptide related bulk drug substances should be recommended for inclusion on the Section 503A Bulks List.

SubstanceCommittee resultReported tallyFDA approved?
BPC 157Recommended8 yes, 6 no, 1 abstentionNo
KPVRecommended8 yes, 6 no, 1 abstentionNo
TB 500Recommended8 yes, 6 no, 1 abstentionNo
MOTS cRecommended7 yes, 5 no, 2 abstentionsNo
EpitalonRecommended7 yes, 4 no, 1 abstentionNo
SemaxRecommended8 yes, 5 no, 1 abstentionNo
Emideltide, also called DSIPNot recommended7 no, 6 yes, 1 abstentionNo

Some members did not vote on every substance because participation varied by session and topic. The reported tallies reflect the committee votes covered by independent reporting.

Regulatory meaning

What a favorable vote actually means

The committee recommended that FDA consider allowing the six favored substances to move toward the Section 503A compounding pathway. Section 503A concerns ingredients that licensed pharmacies may use to prepare patient specific compounded drugs under qualifying conditions.

AdvisoryThe committee advises FDA. Its votes do not bind the agency.
CompoundingThe question involved potential pharmacy compounding, not ordinary retail supplement approval.
Patient specific503A compounding generally involves a prescription for an identified patient and statutory conditions.

The limits

What did not happen

  • None of the seven substances became an FDA approved drug.
  • The committee did not establish that any substance is safe or effective for a marketed use.
  • The vote did not immediately place the favored substances on the final 503A Bulks List.
  • The vote did not approve products sold by Neuvéra or any other company.
  • The decision did not erase FDA's published concerns about limited safety information, impurities, and immunogenicity.
Why this distinction matters: Drug approval requires an application supported by evidence that FDA reviews for a specific product and use. A 503A bulk ingredient recommendation answers a different, narrower compounding question.

Next steps

What happens after the vote

FDA must decide how to respond to the nonbinding recommendations. Any movement toward formal inclusion can require agency action and rulemaking. Until that occurs, the July vote should be described as a committee recommendation, not a final authorization.

For readers, the practical move is to watch FDA's meeting record and future compounding updates rather than treating headlines or social posts as the final legal status.

Primary and independent reporting

Sources

  1. FDA: July 23 and 24, 2026 Pharmacy Compounding Advisory Committee meeting record
  2. FDA: Bulk drug substances that may present significant safety risks
  3. Reuters: First day advisory votes on BPC 157, KPV, TB 500 and MOTS c
  4. TIME: Overview of the committee decisions and debate
  5. ABC News: Six peptides recommended by FDA advisers

Published July 29, 2026. This article is educational and does not provide medical advice. Consult a qualified professional about personal health decisions.

Continue reading

Related regulatory guides

BPC 157What the 8 to 6 recommendation meansSemaxWhat the 8 to 5 recommendation meansTB 500What the 8 to 6 recommendation means